Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Amgen, Inc. and Takeda Oncology.
Clinical Vignette Series: How Can We Be More Strategic in Treatment Planning for Patients with ALL?
Release Date: November 30, 2021
Expiration Date: November 30, 2022
Activity Overview
This educational activity uses a multimedia format combining written passages and brief audio interviews focused on the practical aspects of strategically planning management of patients with ALL from front-line treatment to management of relapsed/refractory (R/R) disease. Expert faculty review the impact of clinical data on patient care, discuss clinical cases, and share forward-looking perspectives on the treatment of ALL.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Inc. and Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop individualized treatment strategies for adult and pediatric patients with ALL based on cytogenetic and immunophenotypic characteristics.
- Assess the clinical utility of minimal residual disease (MRD) assessment and its role in determining prognosis and planning treatment for adults, young adults, and adolescents given a diagnosis of ALL.
- Evaluate the efficacy and safety of current and emerging therapies for ALL.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.Faculty
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant Research Support: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Pfizer, Spectrum Pharmaceutical, Takeda Pharmaceutical.
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington School of Medicine
Seattle, WA
Disclosures: Grant/Research Support: Novartis Pharmaceuticals; Consultant: Amgen, Bristol Myers Squibb, Cepheid, Genentech, Novartis Pharmaceuticals, Takeda Pharmaceutical.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
